Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced ...

Actinium Pharmaceuticals, Inc.  (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Twenty-three new Ngā Ahurei a Te Apārangi Fellows have been elected to the Academy of the Royal Society Te Apārangi. Fellowship recognises researchers, scholars, and innovators throughout Aotearoa New ...

Was there a better way to spend the past decade than on a maddening, deadly, brain-scrambling search for gold hidden ...

Meanwhile, clinical trials suggest GLP-1 receptor agonists could have beneficial effects on cardiovascular diseases, neurodegeneration, kidney disease, cancer and addiction ... analysts Citeline, ...

Recent high-profile discussions in the media have brought increased attention to human papillomavirus (HPV) and its connection to oral cancer. While celebrity revelations might generate headlines ...

A disease detection chatbot powered by generative AI and four cancer tests are among the latest medical devices to receive ...

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net ...

Scientists have developed micro-robots that can perform non-invasive 3D scans to detect and diagnose colorectal cancer in real-time. This breakthrough, achieved through a collaboration between UK ...

Running a 2,000 patient study, with average risk patients in the U.S., to read out by the end of 2025 (eAArly DETECT 2). With eAArly DETECT 2, the Company addresses FDA feedback and prepares for a new ...